BioCryst Pharmaceuticals’ (BCRX) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $11.00 target price on the biotechnology company’s stock, up from their previous target price of $10.00.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Needham & Company LLC raised their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Barclays increased their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday. They set an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Stock Down 0.1 %

BioCryst Pharmaceuticals stock opened at $8.28 on Tuesday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -13.57 and a beta of 1.75. The stock has a 50-day moving average price of $8.05 and a 200 day moving average price of $7.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. During the same period last year, the business earned $0.28 earnings per share. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. Research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Xponance Inc. raised its position in shares of BioCryst Pharmaceuticals by 9.1% during the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 1,242 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. Sei Investments Co. raised its position in shares of BioCryst Pharmaceuticals by 2.8% during the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 1,537 shares during the last quarter. Captrust Financial Advisors raised its position in shares of BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,644 shares during the last quarter. Finally, Creative Planning raised its position in shares of BioCryst Pharmaceuticals by 5.9% during the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.